The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients

MLA

Lane B. Benes, et al. “The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 24, no. 1, June 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1c7caf469954ee9566109191f25ac702&authtype=sso&custid=ns315887.

APA

Lane B. Benes, Matthew J. Sorrentino, Eric J. Brandt, Michael H. Davidson, Linda Lee, & Thomas D Dayspring. (2018). The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 24(1).

Chicago

Lane B. Benes, Matthew J. Sorrentino, Eric J. Brandt, Michael H. Davidson, Linda Lee, and Thomas D Dayspring. 2018. “The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.” Journal of Cardiovascular Pharmacology and Therapeutics 24 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1c7caf469954ee9566109191f25ac702&authtype=sso&custid=ns315887.